Roivant Sciences Ltd. Common Shares (ROIV) : juste valeur

Thèse ACCE

Roivant Sciences is a holding company that develops and commercializes drugs through subsidiaries, with its most prominent asset being the Vtama topical treatment for atopic dermatitis, alongside programs in immunology, neurology and rare disease. The investment case rests on the platform model: Roivant sources drug candidates that are often out-licensed or spun into partially owned subsidiaries, so value depends on pipeline readouts and partnering milestones rather than on a single commercial franchise. Revenue fell 33.5% year over year and the operating margin is deeply negative at -25,408%, reflecting how little product revenue exists against a large development and R&D cost base. Against a $25.0B market cap, the valuation therefore rests almost entirely on pipeline optionality, with no meaningful earnings to anchor it. Our composite score of 41/100 and the absence of index membership suggest this name warrants a deeper look only if the pipeline and milestone timing can be underwritten independently of the current financials.